The Phenomenon of No-Reflow: Physiological Processes and Management

Authors

  • Manar Mostafa EL Zaky
  • Hisham Samir Roshdy
  • Ahmed Abdelhalim Abdel Kawy
  • Mohammed Maher Allam

Keywords:

No-reflow phenomenon, microvascular obstruction, percutaneous coronary intervention, myocardial reperfusion, acute myocardial infarction, coronary microcirculation

Abstract

The no-reflow phenomenon is a serious microvascular complication characterized by inadequate myocardial perfusion despite successful restoration of epicardial coronary artery patency, most commonly following percutaneous coronary intervention (PCI) in acute coronary syndromes. This phenomenon is multifactorial in origin, involving microvascular obstruction due to distal embolization, ischemia–reperfusion injury, endothelial dysfunction, inflammation, and microvascular spasm. No-reflow is associated with larger infarct size, impaired left ventricular function, malignant arrhythmias, and increased short- and long-term mortality. Early recognition and prompt management are crucial, as timely pharmacological and mechanical strategies may partially restore microvascular flow and improve clinical outcomes..

Downloads

Download data is not yet available.

References

[1] Tamis-Holland, J. E., Abbott, J. D., Al-Azizi, K., Barman, N., Bortnick, A. E., Cohen, M. G., et al. 2024. SCAI Expert Consensus Statement on the Management of Patients With STEMI Referred for Primary PCI. J Society for Cardiovas Angiography Interventions, 3, 10-22.

[2] Kaur, G., Baghdasaryan, P., Natarajan, B., Sethi, P., Mukherjee, A., Varadarajan, P., et al. 2021. Pathophysiology, Diagnosis, and Management of Coronary No-Reflow Phenomenon. Int J Angiol, 30, 15-21.

[3] Montone, R. A., Camilli, M., Del Buono, M. G., Meucci, M. C., Gurgoglione, F., Russo, M., et al. 2020. [No-reflow: update on diagnosis, pathophysiology and therapeutic strategies]. G Ital Cardiol (Rome), 21, 4-14.

[4] Annibali, G., Scrocca, I., Aranzulla, T. C., Meliga, E., Maiellaro, F. & Musumeci, G. 2022. "No-Reflow" Phenomenon: A Contemporary Review. J Clin Med, 11, 40-60.

[5] Kloner, R. A., King, K. S. & Harrington, M. G. 2018. No-reflow phenomenon in the heart and brain. Am J Physiol Heart Circ Physiol, 315, 550-562.

[6] Ndrepepa, G. & Kastrati, A. 2023. Coronary No-Reflow after Primary Percutaneous Coronary Intervention-Current Knowledge on Pathophysiology, Diagnosis, Clinical Impact and Therapy. J Clin Med, 12, 30-56.

[7] Ciofani, J. L., Allahwala, U. K., Scarsini, R., Ekmejian, A., Banning, A. P., Bhindi, R., et al. 2021. No-reflow phenomenon in ST-segment elevation myocardial infarction: still the Achilles' heel of the interventionalist. Future Cardiol, 17, 383-397.

[8] Ibanez, B., James, S., Agewall, S., Antunes, M. J., Bucciarelli-Ducci, C., Bueno, H., et al. 2018. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J, 39, 119-177.

[9] Carrabba, N., Amico, M. A., Guaricci, A. I., Carella, M. C., Maestrini, V., Monosilio, S., et al. 2024. CMR Mapping: The 4th-Era Revolution in Cardiac Imaging. J Clin Med, 13, 30-50.

[10] Bulluck, H., Dharmakumar, R., Arai, A. E., Berry, C. & Hausenloy, D. J. 2018. Cardiovascular Magnetic Resonance in Acute ST-Segment-Elevation Myocardial Infarction: Recent Advances, Controversies, and Future Directions. Circ, 137, 1949-1964.

[11] Dawson, L. P., Rashid, M., Dinh, D. T., Brennan, A., Bloom, J. E., Biswas, S., et al. 2024. No-Reflow Prediction in Acute Coronary Syndrome During Percutaneous Coronary Intervention: The NORPACS Risk Score. Circ Cardiovasc Interv, 17, 13-73.

[12] Kumar, D., Ahmed, I., Bardooli, F., Saghir, T., Sial, J. A., Khan, K. A., et al. 2023. Techniques to Treat Slow-Flow/No-Reflow During Primary Percutaneous Coronary Intervention. Cardiovasc Revasc Med, 47, 1-4.

[13] Niccoli, G., Montone, R. A., Ibanez, B., Thiele, H., Crea, F., Heusch, G., et al. 2019. Optimized Treatment of ST-Elevation Myocardial Infarction. Circ Res, 125, 245-258.

[14] Kleinbongard, P., Lieder, H. R., Skyschally, A. & Heusch, G. 2023. No robust reduction of infarct size and no-reflow by metoprolol pretreatment in adult Göttingen minipigs. Basic Res Cardiol, 118, 23-50.

[15] Wang, Y., Wang, B., Ling, H., Li, Y., Fu, S., Xu, M., et al. 2024. Navigating the Landscape of Coronary Microvascular Research: Trends, Triumphs, and Challenges Ahead. RCM, 25, 30-50.

[16] Yu, Y. & Yang, B. P. 2021. Sodium nitroprusside injection immediately before balloon inflation during percutaneous coronary intervention. World J Clin Cases, 9, 48-54.

[17] Khan, K. A., Qamar, N., Saghir, T., Sial, J. A., Kumar, D., Kumar, R., et al. 2022. Comparison of Intracoronary Epinephrine and Adenosine for No-Reflow in Normotensive Patients With Acute Coronary Syndrome (COAR Trial). Circ Cardiovasc Interv, 15, 11-40.

[18] An, S., Huang, H., Wang, H. & Jiang, Y. 2021. Prophylactically injection of Nicorandil to reduce no-reflow phenomenon during PCI in acute STEMI patients: Protocol of a double-blinded, randomized, placebo-controlled trial. Medicine (Baltimore), 100, 25-50.

[19] van Leeuwen, M. A. H., van der Hoeven, N. W., Janssens, G. N., Everaars, H., Nap, A., Lemkes, J. S., et al. 2019. Evaluation of Microvascular Injury in Revascularized Patients With ST-Segment-Elevation Myocardial Infarction Treated With Ticagrelor Versus Prasugrel. Circ, 139, 636-646.

[20] Bulluck, H., Chan, M. H. H., Bryant, J. A., Chai, P., Chawla, A., Chua, T. S., et al. 2019. Platelet inhibition to target reperfusion injury trial: Rationale and study design. Clin Cardiol, 42, 5-12.

[21] De Luca, G., Verburg, A., Hof, A. v. t., ten Berg, J., Kereiakes, D. J., Coller, B. S., et al. 2024. Current and Future Roles of Glycoprotein IIb–IIIa Inhibitors in Primary Angioplasty for ST-Segment Elevation Myocardial Infarction. Biomedicines, 12, 20-23.

[22] Pelliccia, F., Niccoli, G., Zimarino, M., Andò, G., Porto, I., Calabrò, P., et al. 2023. Pathophysiology and Treatment of the No-Reflow Phenomenon in ST-Segment Elevation Myocardial Infarction: Focus on Low-Dose Fibrinolysis during Primary Percutaneous Intervention. RCM, 24, 40-60.

[23] Huang, D., Qian, J., Liu, Z., Xu, Y., Zhao, X., Qiao, Z., et al. 2021. Effects of Intracoronary Pro-urokinase or Tirofiban on Coronary Flow During Primary Percutaneous Coronary Intervention for Acute Myocardial Infarction: A Multi-Center, Placebo-Controlled, Single-Blind, Randomized Clinical Trial. Front Cardiovasc Med, 8, 71-99.

[24] Alyamani, M., Campbell, S., Navarese, E., Welsh, R. C. & Bainey, K. R. 2021. Safety and Efficacy of Intracoronary Thrombolysis as Adjunctive Therapy to Primary PCI in STEMI: A Systematic Review and Meta-analysis. Can J Cardiol, 37, 339-346.

[25] Berwanger, O., Santucci, E. V., de Barros, E. S. P. G. M., Jesuíno, I. A., Damiani, L. P., Barbosa, L. M., et al. 2018. Effect of Loading Dose of Atorvastatin Prior to Planned Percutaneous Coronary Intervention on Major Adverse Cardiovascular Events in Acute Coronary Syndrome: The SECURE-PCI Randomized Clinical Trial. JAMA, 319, 1331-1340.

[26] Abu Arab, T., Sedhom, R., Gomaa, Y. & El Etriby, A. 2024. Intracoronary adenosine compared with adrenaline and verapamil in the treatment of no-reflow phenomenon following primary PCI in STEMI patients. Int J Cardiol, 410, 13-28.

[27] Ma, M., Wang, L., Diao, K. Y., Liang, S. C., Zhu, Y., Wang, H., et al. 2022. A randomized controlled clinical trial of prolonged balloon inflation during stent deployment strategy in primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: a pilot study. BMC Cardiovasc Disord, 22, 30-50.

[28] Egred, M., Bagnall, A., Spyridopoulos, I., Purcell, I. F., Das, R., Palmer, N., et al. 2020. Effect of Pressure-controlled intermittent Coronary Sinus Occlusion (PiCSO) on infarct size in anterior STEMI: PiCSO in ACS study. Int J Cardiol Heart Vasc, 28, 10-52.

[29] Hausenloy, D. J., Chilian, W., Crea, F., Davidson, S. M., Ferdinandy, P., Garcia-Dorado, D., et al. 2019. The coronary circulation in acute myocardial ischaemia/reperfusion injury: a target for cardioprotection. Cardiovasc Res, 115, 1143-1155.

[30] Grancini, L., Diana, D., Centola, A., Monizzi, G., Mastrangelo, A., Olivares, P., et al. 2023. The SALINE Technique for the Treatment of the No-Reflow Phenomenon during Percutaneous Coronary Intervention in STEMI. J Clin Med, 12, 30-50.

[31] Nemani, L. 2023. Practical Approach to Diagnosis, Prevention, and Management of Coronary No-Reflow. Indian J Cardiovasc Dis Women, 8, 65-74.

[32] Mizukami, T., Sonck, J., Gallinoro, E., Kodeboina, M., Canvedra, A., Nagumo, S., et al. 2021. Duration of Hyperemia With Intracoronary Administration of Papaverine. J Am Heart Assoc, 10, 18-56.

[33] Gupta, S. & Gupta, M. M. 2016. No reflow phenomenon in percutaneous coronary interventions in ST-segment elevation myocardial infarction. Indian Heart J, 68, 39-51.

[34] Candreva, A., Gallinoro, E., van 't Veer, M., Sonck, J., Collet, C., Di Gioia, G., et al. 2021. Basics of Coronary Thermodilution. JACC Cardiovasc Interv, 14, 595-599.

[35] Gallinoro, E., Candreva, A., Fernandez-Peregrina, E., Bailleul, E., Meeus, P., Sonck, J., et al. 2022. Saline-induced coronary hyperemia with continuous intracoronary thermodilution is mediated by intravascular hemolysis. Atheroscler, 352, 46-52.

[36] Berry, C., Maznyczka, A. M. & McCartney, P. 2019. Failed myocardial reperfusion during primary PCI: an unmet therapeutic need. EuroIntervention, 14, 1628-1630.

Downloads

Published

2024-12-07

How to Cite

1.
EL Zaky MM, Roshdy HS, Abdel Kawy AA, Maher Allam M. The Phenomenon of No-Reflow: Physiological Processes and Management. J Neonatal Surg [Internet]. 2024 Dec. 7 [cited 2026 Feb. 25];13(1):2116-2. Available from: https://jneonatalsurg.com/index.php/jns/article/view/10002

Issue

Vol. 13 (2024): Journal of Neonatal Surgery

Section

Original Article

License

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

You are free to:

  • Adapt — remix, transform, and build upon the material for any purpose, even commercially.

Terms:

  • Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
  • No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.